3 Undervalued Life Sciences Tools & Services Stocks for Monday, November 11
Discover the top 3 undervalued Life Sciences Tools & Services stocks for Monday, November 11 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Omar Beirat
Omar Beirat
Jack Gilleland
Jack Gilleland
| Share Statistics | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $12.3 | $1,790.4 | 8% |
|
| Shares Out (Mil) | 11.0 | 94.8 | 22% |
|
| Institutional Ownership | 99.8% | 90.0% | 94% |
|
| Float (Mil) | 10.3 | 69.9 | 20% |
|
| Beta | 1.63 | 1.20 | 85% |
|
| Avg Daily Volume (000s) | 107 | 814 | 36% |
|
| Price Change (52-week) |
(64.6%) | 80.2% | 11% |
|
| Growth | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 27.4% | 7.8% | 88% |
|
| Net Income (5yr) | 8.5% | (13.7%) | 52% |
|
| EPS (5yr) | 54.0% | 0.7% | 94 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.0%) | (15.0%) | 52% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.670) | ($2.710) | ($1.110) | |
| Month Ago EPS | na | ($2.710) | ($1.110) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.890) | ($2.710) | ($1.110) | |
| Year/Year Chg | (11.4%) | (44.1%) | (89.3%) | |
| Financials | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $29 | $785 | 15% |
|
| Net Income (TTM) (Mil) | ($32) | ($14) | 20% |
|
| EPS (TTM) | ($4.204) | ($0.200) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($19) | $53 | 15% |
|
| Net Cash Flow (TTM) (Mil) | $1 | ($4) | 48% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $270 | 26% |
|
| Enterprise Value (Q1) (Mil) | $16 | $2,444 | 10% |
|
| Valuation | BNGO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.32 | 2.92 | 5% |
|
| P/E | na | 43.7 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | BNGO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 47.0% | 47.6% | 59% |
|
| Net Margin | (109.9%) | (2.9%) | 7% |
|
| ROA | (44.1%) | (2.8%) | 13% |
|
| ROE | (73.8%) | (4.5%) | 12% |
|
| Liabilities to Assets | 42.2% | 43.0% | 33% |
|
| F-Score | 5 | 5 | 51% |
|
Bionano Genomics, Inc. did not pass any screens on 7/31/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors